Hennig H, Haase D, Kirchner H
Institut für Immunologie und Transfusionsmedizin, Medizinische Universität zu Lübeck, Deutschland.
Beitr Infusionsther Transfusionsmed. 1996;33:231-4.
In 1994 we tested 30,208 blood donations in Lübeck with the Abbott HCV EIA 2.0. 88 specimens of 47 blood donors who were repeatedly reactive were the basis of comparative investigations with the Chiron RIBA HCV 2.0 and 3.0, the Abbott Matrix HCV, the Wellcozyme HCV Western Blot (Murex) and the PCR (Amplicor HCV Test, Roche Diagnostic Systems). Our results suggest that the minimal prevalence of HCV RNA amounts to approximately 0.13%, the incidence per year to 0.013%. The minimal prevalence of anti-HCV amounts to 0.27%. Anti-core antibodies are the most frequent anti-HCV antibodies. They may be the only detectable antibodies during the early phase of the infection. The Chiron RIBA HCV 3.0 with the synthetic peptide c22p is not sufficiently sensitive for anti-core antibodies and may therefore fail to recognize viremic specimens.
1994年，我们使用雅培丙肝病毒酶免疫分析2.0对吕贝克的30208份献血样本进行了检测。47名多次检测呈反应性的献血者的88份样本，成为了与凯龙重组免疫印迹法丙肝病毒2.0和3.0、雅培丙肝病毒基质检测、Wellcozyme丙肝病毒免疫印迹法（Murex）以及聚合酶链反应（Amplicor丙肝病毒检测，罗氏诊断系统）进行对比研究的基础。我们的结果表明，丙肝病毒核糖核酸的最低流行率约为0.13%，每年的发病率为0.013%。丙肝病毒抗体的最低流行率为0.27%。核心抗体是最常见的丙肝病毒抗体。它们可能是感染早期唯一可检测到的抗体。带有合成肽c22p的凯龙重组免疫印迹法丙肝病毒3.0对核心抗体的敏感性不足，因此可能无法识别病毒血症样本。
